Please ensure Javascript is enabled for purposes of website accessibility

Americans Celebrate Their Independence With Record-Breaking Travel Numbers

21 minutes ago

US House Republicans Head Toward Final Vote on Trump’s Sweeping Tax-Cut Bill

1 hour ago

US Supreme Court to Decide Legality of Transgender School Sports Bans

1 hour ago

Nvidia Set to Become the World’s Most Valuable Company in History

2 hours ago

Poll: 41% in US ‘Extremely Proud’ to Be American, Near Historic Low

2 hours ago

Trump Vowed to Dismantle MS-13. His Deal With Bukele Threatens That Effort.

23 hours ago

Ukraine Voices Concern as US Halts Some Missile Shipments

24 hours ago

What’s Next for Sean ‘Diddy’ Combs After His Sex Trafficking Trial?

1 day ago
NorCal Doctor: Not Everyone Needs COVID-19 Testing
TLBBHMAP3-U010ALB5ANM-348f959abae2-512-300x300-1
By Jim Jakobs, Digital Producer
Published 5 years ago on
April 10, 2020

Share

“We almost don’t need them for everybody,” Dr. Roberta Luskin-Hawk says of COVID-19 tests.
Her reasoning is explained below, but it also comes from a wealth of medical experience. She is an infectious disease specialist who worked with Dr. Anthony Fauci in Chicago during the AIDS epidemic. And she is the chief executive for St. Joseph Health in Eureka.
Her hospital just began a clinical trial for the antiviral drug remdesivir and has enrolled one patient so far.
GV Wire spoke to Luskin-Hawk via Zoom on Friday morning.

Q&A with Dr. Luskin-Hawk

GV Wire: Abbott Labs is producing about 50,000 COVID-19 test kits a day. Is it likely we’ll ever get enough test kits for everyone?

A test for someone with no symptoms is pretty meaningless because they could pick it up a week from now. But tests that are also in development are these antibody tests, which will be a blood test that will be simpler and easier to do. It will be for someone who has already been exposed and may have some immunity. So I think there will be combinations of testing, but the need to test for the virus itself is not something we need to do in every person.

Of all the clinical trials you could have joined, why remdesivir?

As an infectious disease doctor, I was intrigued by something that had specific antiviral activity. But I think the other compelling anecdote and it is strictly related to one case which is not sufficient to know how the drug works, but the first case report in the U.S., from Washington state was a man who was in ICU and was given remdesivir. This was reported in the New England Journal of Medicine … and the patient went on to do well.

What does remdesivir do?

These drugs interfere with (COVID-19) multiplying. This particular drug was developed in part to treat ebolavirus and then was studied in two other types of coronaviruses, what’s called SARS and MERS and both of them are kind of causes of the novel coronavirus we’re dealing with now.

How many patients are in the remdesivir trial?

We’ve enrolled one person so far. But enrollment across the country is so active these trials might be fully enrolled, even in a couple weeks, the way it’s going.

How has your patient responded?

I understand the patient is doing well but that’s probably all I can say. Because of privacy.

Do you have insights on some of the other vaccine trials?

I don’t have in-depth knowledge. I know there’s a vaccine that was developed in Israel that I understand may start trial as early as June. … There are many people trying to develop vaccines.
[covid-19-tracker]

Coronavirus Patients Rush to Join Studies of Gilead Drug

Coronavirus patients around the world have been rushing to join remdesivir studies that opened in hospitals in the last few weeks.
Interest has been so great that the U.S. National Institutes of Health is expanding its study, which has nearly reached its initial goal of 440 patients. The drug’s maker, California-based Gilead Sciences, is quickly ramping up its own studies, too.
Remdesivir is given through an IV. It’s designed to interfere with an enzyme that reproduces viral genetic material.
Gilead supplied remdesivir for two studies in China. Results are expected by the end of April.

Cost to Produce the Medicines

According to Reuters, a study released Friday in the Journal of Virus Eradication, researchers, including Howard University chemist Joseph Fortunak, examined the cost of manufacturing medicines in recent or ongoing COVID-19 trials.
Using prices for active pharmaceutical ingredients to build estimates, they said Gilead Science’s experimental drug remdesivir, originally for Ebola, could be made for as little as $0.93 for a day’s supply.
Gilead said the figure does not “accurately reflect” manufacturing costs at scale, but it did not give those costs.
Gilead can produce 140,000 remdesivir treatment courses near-term, and 1 million-plus by December, it has projected.

DON'T MISS

What Are Fresno Real Estate Experts Predicting for 2025 and Beyond?

DON'T MISS

First California EV Mandates Hit Automakers This Year. Most Are Not Even Close

DON'T MISS

Madera County Deputy Injured, Wanted Felon Arrested After Violent Struggle

DON'T MISS

San Luis Obispo County Wildfire Burns More Than 3,000 Acres. No Containment Yet

DON'T MISS

Wired Wednesday: Why Is State Lawmaker Taking Aim at Rooftop Solar?

DON'T MISS

Two Visalia Men Sentenced in 2021 Motel Killing

DON'T MISS

Ex-Jan. 6 Defendant Gets Life in Prison for Plot to Kill FBI Agents

DON'T MISS

Del Monte Files for Bankruptcy. Gets Nearly $1B to Keep Producing Through Process

DON'T MISS

Who is Running for Fresno Area Offices in 2026? An Updated Look

DON'T MISS

CIA Review Finds Flaws but Does Not Dispute Finding Putin Sought to Sway 2016 Vote to Trump

DON'T MISS

Poorest Americans Dealt Biggest Blow Under Senate Republican Tax Package

DON'T MISS

Check Out Newest Downtown Mural. It’s a Spectacular Tribute to Fresno Artisans

UP NEXT

Poorest Americans Dealt Biggest Blow Under Senate Republican Tax Package

UP NEXT

Check Out Newest Downtown Mural. It’s a Spectacular Tribute to Fresno Artisans

UP NEXT

CHP Officer Dies in Line of Duty After Medical Emergency While on Patrol

UP NEXT

Downtown Housing Could Rise in Many California Cities, but Barriers Remain

UP NEXT

Bryan Kohberger to Plead Guilty to Murders of Four Idaho Students

UP NEXT

Valley Children’s Goes Into News Business to Highlight Stories at the Hospital

UP NEXT

Ukraine Voices Concern as US Halts Some Missile Shipments

UP NEXT

Poll: Most Americans Say National Divide, Political Violence Threaten Democracy

UP NEXT

Paramount Settles With Trump Over ‘60 Minutes’ Interview for $16 Million

UP NEXT

Four Rescued After Kings River Float Turns Dangerous

US Imposes New Sanctions Targeting Iran Oil Trade, Hezbollah, Treasury Dept Says

1 hour ago

Keep Pets Safe on 4th of July: Fresno County Animal Shelter Offers Tips

1 hour ago

US House Republicans Head Toward Final Vote on Trump’s Sweeping Tax-Cut Bill

1 hour ago

US Supreme Court to Decide Legality of Transgender School Sports Bans

1 hour ago

Supreme Court’s Conservatives Leaned Into US Culture Wars With Transgender Cases

1 hour ago

San Luis Obispo’s Madre Fire Grows to 35,000 Acres, More Evacuations Ordered

1 hour ago

Nvidia Set to Become the World’s Most Valuable Company in History

2 hours ago

There Are Fresno Area Fireworks Shows Galore Through Sunday

2 hours ago

Poll: 41% in US ‘Extremely Proud’ to Be American, Near Historic Low

2 hours ago

House Republicans Say They Expect to Vote Tonight on Trump’s Tax-Cut Bill

17 hours ago

Americans Celebrate Their Independence With Record-Breaking Travel Numbers

AAA projects a record 72.2 million people in the U.S. will travel 50 miles or more from home over the Independence Day holiday period from l...

21 minutes ago

21 minutes ago

Americans Celebrate Their Independence With Record-Breaking Travel Numbers

U.S. and Chinese flags are seen in this illustration taken March 20, 2025. (Reuters File)
33 minutes ago

US Paves Way to Resume Ethane Exports to China Amid Trade Truce

A general view of the U.S. Supreme Court building in Washington, U.S., June 1, 2024. (Reuters File)
38 minutes ago

US Supreme Court Won’t Consider Reviving Montana Abortion Parental Consent Law

Treasury Secretary Scott Bessent speaks to reporters at the U.S. Capitol as Republican lawmakers struggle to pass U.S. President Donald Trump?s sweeping spending and tax bill, on Capitol Hill in Washington, D.C., U.S., June 27, 2025. (Reuters File)
1 hour ago

US Imposes New Sanctions Targeting Iran Oil Trade, Hezbollah, Treasury Dept Says

1 hour ago

Keep Pets Safe on 4th of July: Fresno County Animal Shelter Offers Tips

A view shows the dome of the U.S. Capitol, in Washington, D.C., U.S., July 3, 2025. (Reuters File)
1 hour ago

US House Republicans Head Toward Final Vote on Trump’s Sweeping Tax-Cut Bill

A general view of the U.S. Supreme Court building in Washington, U.S., June 1, 2024. (Reuters File)
1 hour ago

US Supreme Court to Decide Legality of Transgender School Sports Bans

Demonstrators attend a Transgender Day of Visibility rally on the National Mall in Washington, D.C., U.S., March 31, 2025. (Reuters File)
1 hour ago

Supreme Court’s Conservatives Leaned Into US Culture Wars With Transgender Cases

Help continue the work that gets you the news that matters most.

Search

Send this to a friend